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Aortic stenosis (AS) is characterized by both progressive narrowing of the valve and the 
hypertrophic response of the left ventricle that ensues (LV) (1). Whilst initially adaptive, the 
hypertrophic response ultimately decompensates and patients transition from hypertrophy to 
heart failure, symptom development and adverse events. Pathology studies have 
demonstrated that this transition is driven predominantly by progressive myocyte cell death 
and myocardial fibrosis (2). Using cardiovascular magnetic resonance (CMR), the late 
gadolinium enhancement (LGE) technique can identify areas of midwall replacement fibrosis 
in patients with aortic stenosis. Recent studies have demonstrated the association between 
LGE and other markers of LV decompensation and its presence portends adverse short-term 
prognosis (3–5). We present the first prospective study investigating the association between 
midwall LGE and long-term mortality in patients with aortic stenosis.    
     Patients with moderate and severe AS undergoing CMR with gadolinium contrast at the 
Royal Brompton Hospital, London, UK from 2003-2008 were included as previously 
described (4). CMR was undertaken in 143 consecutive patients: age 68±14 years, 97 (68%) 
male, aortic valve area 1.0±0.3cm2, left ventricular ejection fraction  (LVEF) 58±19%, 81 
(57%) with known coronary artery disease (4). Patients were then followed for a median of 
five years for all-cause mortality and AS-related mortality (deaths where AS was either the 
primary cause or a major contributor as assessed by an independent, blinded panel of experts 
from death certificates and hospital notes). 
     On CMR, 54 (38%) patients had midwall fibrosis (linear, non-linear, focal, multi-focal or 
subepicardial (4)), 40 (28%) had subendocardial infarction-pattern LGE and 49 (34%) had no 
LGE. During a median follow up of 5 years (IQR 2.5, 5), 87 patients (61%) underwent aortic 
valve replacement (AVR). Forty-four patients (31%) died: 21/54 (39%) in the midwall 
fibrosis group (4 patients had AVR prior to death), 16/40 (40%) in the subendocardial 
infarction-pattern group (4 patients had AVR prior to death) and 7/49 (14%) in the no LGE 
3 
group (2 patients  had AVR prior to death). On univariate analysis both patients with midwall 
fibrosis [HR 2.55 (95% CI 1.28-5.15, p=0.008)] and subendocardial infarction-pattern LGE 
[HR 2.71 (95% CI 1.31-5.62, p=0.007) showed increased all-cause mortality when compared 
to patients with no LGE (Figure 1A). On multivariate analysis, midwall fibrosis remained an 
independent predictor of mortality with incremental value to LVEF [HR 2.64 (95% CI 1.07-
2.88 p=0.035)] alongside age [HR 1.03 (95% CI 1.00-1.06, p=0.044)], LVEF [HR 0.97 (95% 
CI 0.94-0.99, p=0.006)] and wall thickness [HR 0.88 (95% CI 0.77-0.99, p=0.026)]. In 
contrast, subendocardial infarction-pattern LGE did not remain significant suggesting that its 
effect is mediated via reduced LVEF.  
     The 23 AS-related deaths followed a similar pattern to all-cause mortality; being more 
common in patients with midwall 12/54 (22%) and infarction-pattern 8/40 (20%), compared 
to no LGE 3/49 (6%), both p<0.05. Two patients from the midwall, three from the infarction 
and one from the no LGE groups had AVR between CMR and  death.  
      Our results demonstrate that midwall fibrosis on CMR LGE is an independent predictor 
of mortality out to 5 years and  of incremental prognostic value to LVEF  (Figure 1B). These 
data would support midwall LGE as a useful marker in the risk stratification of patients with 
aortic stenosis. 
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Figure Legend 
Figure 1: Midwall fibrosis on CMR is associated with an adverse 5-year prognosis in 
aortic stenosis of incremental value to ejection fraction.  
Panel A, Kaplan-Meier estimator curves for all-cause mortality demonstrating an adverse 
prognosis in patients with midwall (orange line) compared to no LGE (blue line) and 
subendocardial infarction-pattern LGE (green line) compared to no LGE. On multivariable 
analysis midwall fibrosis remained significantly associated with prognosis but subendocardial 
infarction-pattern did not. The survival pattern was similar when aortic stenosis-related 
deaths only were considered.  
Panel B, Cox proportional hazards model using Ejection Fraction (EF) and midwall LGE 
presence/absence as predictors of survival. The orange line estimates survival when midwall 
fibrosis is present and the blue line when absent for a given EF. For example, in a patient 
with EF=50% and no fibrosis 5-year survival  is estimated at 77%, but decreases  to 55% in 
the presence of midwall LGE. The green line indicates survival in patients with infarction 
fibrosis. 
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